Evaluation of Vascular Structure in Elderly Using High-frequency Ultrasound and Construction of a Multimodal Risk Assessment System for Cardiovascular Diseases: a Multicenter Study

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Jan 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better assess and understand cardiovascular diseases, like coronary heart disease and stroke, particularly in elderly patients. Researchers want to use advanced imaging techniques, such as high-frequency ultrasound and other non-invasive methods, to look at changes in the blood vessels of older adults. The goal is to create a smart system that can help identify those at risk for serious heart and brain conditions, making it easier for doctors to provide timely care and improve health outcomes.

To be eligible for this study, participants must be 60 years or older and have specific ultrasound images and clinical data related to their heart and blood vessels. The trial will follow participants over time, checking in every six months to see if they experience any major health events, such as heart attacks or strokes. This research is important because it aims to gather valuable information from at least 20,000 elderly individuals, which could lead to better diagnosis and treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 60 years
• • All patients had original ultrasound images of bilateral carotid arteries with DICOM format and arteriosclerosis clinical and laboratory data
• • Original data of CCTA or examination results in the baseline status are needed for CHD patients
• • Original data of intracranial artery MRA or examination results in the baseline status are needed for patients with ischemic stroke.
• Exclusion Criteria:
• • Age is \<60 years old
• • Severe cardiac insufficiency, New York Heart Association(NYHA) class IV and (or) left ventricular ejection fraction \<30%
• • Uncontrollable severe hypertension (systolic blood pressure≥ 180 mmHg or diastolic blood pressure≥ 110 mmHg) or uncontrollable severe diabetes mellitus, i.e., diabetes mellitus complicated with acute complications (including diabetic ketoacidosis and hypertonic hyperglycemic nonketosis coma), or acute hyperglycemic state (random blood glucose\> 16.7mmol/L and (or) blood ketone 1.0-3.0mmol/L) without acute complications
• • Severe valvular disease (moderate regurgitation and / or stenosis in each valve)
• • Various cardiomyopathy caused by hypertrophic cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy, myocardial amyloidosis
• • Severe arrhythmia: persistent atrial fibrillation or atrial flutter, degree II 2 and above atrioventricular block, complete left bundle branch block
• • Severe hepatic and renal insufficiency (glutamate transaminase and / or glutamine transaminase\> 3 times the upper limit of normal value, Blood creatinine\> 134 μmol/L or an estimated glomerular filtration rate of \<60ml/min/1.73m2)
• • Severe chronic obstructive pulmonary disease or asthma
• • Severe non-cardiovascular disease (malignant tumor, thyroid disease, infection, connective tissue disease)
• • Mental retardation or mental disorders
• • Life expectancy \<3 years due to various factors
• • Refusal to sign informed consent
• • Allergy to contrast agent should also be ruled out for patients undergoing CCTA for CHD.